Reformulating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines
with variant strains is being pursued to combat the global surge in infections. We hypothesize …

Currently approved COVID-19 vaccines administered parenterally induce robust systemic
humoral and cellular responses. While highly effective against severe disease, there is …

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has
dramatically expedited global vaccine development efforts 1 , 2 – 3 , most targeting the viral ‘spike’ …

The durability of infection-induced SARS-CoV-2 immunity has major implications for reinfection
and vaccine development. Here, we show a comprehensive profile of antibody, B cell …

The hallmarks of COVID-19 are higher pathogenicity and mortality in the elderly compared
to children. Examining baseline SARS-CoV-2 cross-reactive immunological responses, …

An improved understanding of human T cell-mediated immunity in COVID-19 is important
for optimizing therapeutic and vaccine strategies. Experience with influenza shows that …

To better understand primary and recall T cell responses during coronavirus disease 2019 (COVID-19),
it is important to examine unmanipulated severe acute respiratory syndrome …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and vaccination
elicit CD4 + T cell responses to the spike protein, including circulating follicular helper T (cT …

Vaccination against SARS-CoV-2 protects from infection and improves clinical outcomes in
breakthrough infections, likely reflecting residual vaccine-elicited immunity and recall of …

High-risk groups, including Indigenous people, are at risk of severe COVID-19. Here we
found that Australian First Nations peoples elicit effective immune responses to COVID-19 …